Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven ...
A new study published in The Lancet Microbe reports the first twice-yearly injectable HIV treatment regimen—combining ...
With Gift Aid, your generous donation of £10 would be worth £12.50 at no extra cost to you. Yes, I want to Gift Aid any donations made to NAM now, in the future and in the past four years I am a UK ...
A redesigned cancer immunotherapy is showing striking early results after decades of disappointment with similar drugs.
For years, one of the most powerful weapons against certain blood cancers, called CAR-T cell therapy, has required an ...
Although HIV infection remains a global public health challenge, ART has transformed it from a fatal illness to a manageable ...
Unlike current treatments on the market for hereditary angioedema, navenibart requires dosing only every 3-6 months.
In participants with highly active disease, the unadjusted annualized relapse rate (ARR) at Week 96 was 0.145 for BRIUMVI versus 0.496 for teriflunomide, representing a 70.8% relative reduction ...
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosis (RMS), ...
Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...
Sun Pharmaceutical Industries Limited. Sun Pharma announces US FDA acceptance of supplemental Biologics License Application ...
Henry Ford Health has treated the first Michigan patient outside clinical trials with Roctavian, the newly approved gene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results